Claudio Counoupas

TL;DR: This review will summarize the current understanding of the protective immune responses following M. tuberculosis infection or vaccination, with a particular focus on vaccines that have recently entered clinical trials.

TL;DR: The current challenge is to identify the most suitable candidates to progress from early to late stage clinical trials, in order to deliver a vaccine that can control and hopefully eliminate the global threat of TB.

TL;DR: An unappreciated role for Ag85B in the interaction of mycobacteria with host cells is revealed and indicates that single protective antigens are dispensable for protective immunity induced by BCG.

TL;DR: The possibility to modify the above tested parameters during material synthesis and manufacture could allow to bound the inflammatory potency of the PEtU-PDMS devices and render them excellent candidates for cardiovascular reconstruction.

TL;DR: In this article, the early immune events following the intrapulmonary delivery of a vaccine incorporating the adjuvant delta-inulin were defined, and the early inflammatory response showed vaccine-induced innate cell recruitment to lungs and local lymph nodes was transient and non-polarised, correlating with an increase in pulmonary chemotactic factors.